NEW YORK, Sept. 2, 2015 /PRNewswire/ -- About Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia is a malignant condition characterized by increased production of lymphocytes. It has been observed that the cancer first affects B-lymphocytes and then it can spread to other parts of the body. This leukemia is diagnosed mostly at later stages because of the slow buildup of the cancerous cells. During the course of the disease, the malignancy spreads to the spleen, liver, and lymph nodes. The course of the disease is heterogeneous, and prognosis is difficult. Symptoms include swelling of the lymph nodes, fatigue, fever, infection, pain beneath the ribs, and weight loss. Chronic lymphocytic leukemia can be treated with radiation, steroids, chemotherapy, targeted therapy, transplants (bone marrow, stem cell), and surgical procedure to remove the spleen (splenectomy).
Technavio's analysts forecast the global chronic lymphocytic leukemia therapeutics market to grow at a CAGR of 18.52% over the period 2014-2019.
Covered in this Report
In this report, Technavio covers the present scenario and growth prospects of the global chronic lymphocytic leukemia therapeutics market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various drugs used in the treatment of chronic lymphocytic leukemia.
Based on the type of molecule, we group the market into two categories:
- Biologics
- Small molecules
Based on the route of administration, we group the market into two:
- Oral
- Parenteral
This report includes a discussion of the market in the following three regions:
- Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
- EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle
Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
- APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India. APAC is a major untapped market with many leading vendors in the global chronic lymphocytic leukemia therapeutics market.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. In addition, it discusses the major drivers and challenges, as well as the key trends.
Key Regions
- Americas
- APAC
- EMEA
Key Vendors
- F. Hoffmann-La Roche
- Novartis
- Teva Pharmaceutical Industries
Other Prominent Vendors
- Actavis
- Amgen
- Aryogen
- Astellas
- Bristol-Myers Squibb
- Eagle Pharmaceuticals
- Eisai
- Fresenius Kabi
- Genmab
- Gilead Sciences
- H. Lundbeck
- Hospira
- idd biotech
- Immunomedics
- Johnson & Johnson
- Mundipharma
- Mylan
- Noxxon
- Ono Pharmaceutical
- PDL BioPharma
- Pfizer
- Pharmacyclics
- Regeneron
- Sagent Pharmaceutical
- Sanofi
- SymBio Pharmaceuticals
- TheraMAB
Key Market Driver
- Increase in Patient Pool
- For a full, detailed list, view our report
Key Market Challenge
- Unknown Disease Etiology
- For a full, detailed list, view our report
Key Market Trend
- Strategic Alliances
- For a full, detailed list, view our report
Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Read the full report: http://www.reportlinker.com/p03170203-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
